Top Markets
#1 Siacoin Siacoin +16.51%
#2 Seeker Seeker +13.30%
#3 Cash Cat Cash Cat +12.44%
#4 DogBull DogBull +9.95%
#5 0G 0G +9.07%
#6 Useless Coin Useless Coin +5.74%
#7 StonkBroker StonkBroker +4.63%
#8 The Black Bull The Black Bull +4.56%
#9 Akedo Akedo +4.31%
#10 Story Story +4.27%
Coin of the day
Siacoin Siacoin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
EirGenix Inc. EirGenix Inc.

EirGenix Inc.

6589
Rang in aandelen #14109
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions... EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
Aandeelprijs
$1.46
Laatst gesynchroniseerd: 2026-07-28
Marktkapitalisatie
$435.25M
Verandering (1 dag)
-2.34%
Verandering (1 jaar)
-25.65%
Land
TW
Handel EirGenix Inc. (6589)

Categorie

Healthcare
Winst voor EirGenix Inc. (6589)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van EirGenix Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van EirGenix Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH